SpyGlass Pharma, Inc. (SGP)

SpyGlass Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Selling, General & Admin	-	7.08	4.27
Research & Development	-	19.98	9.96
Operating Expenses	-	27.06	14.23
Operating Income	-35.58	-27.06	-14.23
Interest Expense (Income)	-2.24	-1.32	-0.91
Other Expense (Income)	2.38	3.42	-
Pretax Income	-35.71	-29.16	-13.32
Net Income	-35.71	-29.16	-13.32
Free Cash Flow	-30.42	-24.02	-12.49
EBITDA	-37.45	-30.21	-14.11
Depreciation & Amortization	0.5	0.27	0.12
EBIT	-37.95	-30.48	-14.23

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).